On March 25, 2025 Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing immunogenic small molecule approaches in oncology, reported the company will present immuno-profiling data from two Phase 2 studies of PT-112 monotherapy at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, which will be held from April 25 – 30, 2025 at the McCormick Place Convention Center in Chicago, IL (Press release, Promontory Therapeutics, MAR 25, 2025, View Source [SID1234651471]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster will present immune activation effects observed with PT-112 monotherapy in patients with pretreated thymic epithelial tumors and late-line metastatic castration-resistant prostate cancer, including increases in activated T cells and NK cells, modulation of blood cytokines, and the emergence of novel T cell clones.
Poster Session Details
Title: Anti-Cancer Immune Effects of PT-112 Monotherapy Across Two Disease Indications
Location: Poster Section 28, McCormick Place Convention Center, Chicago, Illinois
Poster Board Number: C128
Published Abstract Number: 5819
Session: Immune Response to Therapies
Session date + time: 4/29/2025 2-5PM CDT